Zenas BioPharma shares jump 12.02% after-hours after announcing $287.5 million strategic investment.

Zenas BioPharma surged 12.02% in after-hours trading following the announcement that it secured a $287.5 million strategic investment. The funding, provided by an undisclosed global biopharma industry capital firm, will support the advancement of multiple preclinical and early-stage clinical programs, including novel Treg-targeting therapies. This development highlights growing confidence in Zenas’ immunotherapy platform and its potential to address major diseases such as cancer and autoimmune disorders.